New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma. The clinical-stage biopharmaceutical company is focused on cell therapy for autoimmune diseases. The partnership aims to advance the development of novel in vivo chimeric antigen receptor T-cell (CAR-T) therapies for autoimmune diseases, which could significantly enhance the company’s clinical prospects. Read Also: Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus Cartesian Therapeutics Licenses In Vivo CAR-T Platform With WestGene WestGene will receive an upfront payment and is eligible for potential development and commercial milestone payments. The collaboration is expected to initiate a clinical trial in the second half of 2026, with clinical data anticipated in the first half of 2027, focusing on patients with myasthenia gravis. RNAC Technical Outlook: Key Levels And Momentum The stock’s current price of $6.50 is approximately 7.3% below its 20-day simple moving average (SMA) of $7.01, indicating a short-term bearish trend. The moving average convergence divergence (MACD) is currently below its signal line, suggesting that momentum is fading, which could limit the upside unless the stock can regain that baseline. Support and resistance levels are crucial for understanding potential price movements. Key Resistance: $7.50 — a nearby level where rebounds can stall. Key Support: $6.00 — a nearby level where buyers previously stepped in. Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $29.75. Recent analyst moves include: Wedbush: Outperform (Maintains Target to $38.00) (May 27) Needham: Buy (Lowers Target to $40.00) (May 26) HC Wainwright & Co.: Buy (Lowers Target to $25.00) (May 12) How RNAC Ranks On Momentum In Benzinga Edge Below is the Benzinga Edge scorecard for Cartesian Therapeutics, highlighting its strengths and weaknesses compared to the broader market: Momentum: Weak (Score: 5.14) — Stock is showing weak performance indicators. The Verdict: Cartesian Therapeutics’s Benzinga Edge signal reveals a weak profile, indicating challenges in maintaining momentum. Investors may need to monitor upcoming developments closely as the company navigates its strategic partnerships and clinical trials. RNAC Price Action: Cartesian Therapeutics shares were up 17.75% at $6.90 at the time of publication on Tuesday, according to Benzinga Pro data. Photo: motorolka/Shutterstock Read Also: Sam Altman-Affiliated AI Token WLD Surges Over 100% In A Month Despite Layoffs